Could two HPV shots be enough? new study tests simpler vaccine schedule
NCT ID NCT04206813
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether a 2-dose schedule of the HPV vaccine (Gardasil 9) is as effective as the standard 3-dose schedule in women aged 16 to 45. Researchers will measure antibody levels in 352 women to compare immune responses. If the 2-dose regimen works well, it could simplify vaccination and reduce costs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Gardasil 9 (HPV vaccine)
- What this could lead to
- If successful, this could show that a 2-dose HPV vaccine schedule is effective for women up to age 45, making vaccination simpler and cheaper.
- What could go wrong
- This is a small, single-center study, not a large Phase 3 trial. The results may not apply to all populations, and the 2-dose schedule might not provide long-term protection as strong as 3 doses.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Boston Medical Center
Boston, Massachusetts, 02118, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a daily supplement help the body fight off HPV?
- At-Home HPV tests could save lives of women with HIV
- New immune therapy aims to train body to clear HPV
- Could a tiny HPV shot still protect? small study tests lower dose
- New Self-Sampling and digital colposcopy could speed up cervical cancer detection
- Could a smaller HPV vaccine dose still protect adults?